Management of Advanced Small Bowel Cancer
- 5 November 2018
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 19 (12) , 1-14
Abstract
Opinion statement Small bower cancer is a rare disease, despite its incidence is increasing in the last decade. Both benign and malignant tumors can arise from the small intestine. The main histological cancer types are adenocarcinomas, neuroendocrine tumors, sarcomas, gastrointestinal stromal tumors (GISTs), and lymphomas. Due to the rarity of these malignances, all the currently available data are based on small studies or retrospective series, although recent breakthroughs are redirecting our approach to these patients. Immunotherapy for small bowel adenocarcinomas, several multikinase inhibitors in resistant GIST patients, as well as everolimus and 177Lu-DOTATATE in neuroendocrine tumors are only few of the novel therapeutic options that have changed, or may change in the future, the therapeutic landscape of these rare cancers. Larger and more powerful studies on the molecular profile of these tumors may lead to a better design of clinical trials, which eventually would provide our patients with more efficacious treatments to improve both overall survival and quality of life.Keywords
Funding Information
- National Cancer Institute (P30CA014089)
This publication has 90 references indexed in Scilit:
- Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesisOncogene, 2012
- One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal TumorJAMA, 2012
- Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch SyndromeJAMA, 2011
- Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective studyBMC Cancer, 2011
- Epidemiology of cancer of the small intestineWorld Journal of Gastrointestinal Oncology, 2011
- Cetuximab in small bowel adenocarcinoma: a new friend?British Journal of Cancer, 2010
- Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromesBest Practice & Research Clinical Endocrinology & Metabolism, 2010
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- A Prospective Study of Meat and Fat Intake in Relation to Small Intestinal CancerCancer Research, 2008
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998